Merck raises stakes in lung cancer as rivals close in

LOS ANGELES (Reuters) - Merck& Co Inc, maker of the only immunotherapy approved for patients newly-diagnosed with the most common type of lung cancer, could solidify its lead by playing the long game, even as rivals edge closer.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news